Biopharma
Biointron unveils AI-powered antibody discovery platform delivering CHO expression data in just one day
The launch comes as AI models rapidly expand the ability to generate hundreds or thousands of antibody candidates in a single design cycle
- By IPP Bureau
| July 28, 2026
Biointron Biological has launched RushData, a next-generation integrated platform designed to accelerate AI-driven antibody discovery by delivering high-quality experimental data in days instead of weeks.
Built to address a critical bottleneck in computational antibody design, RushData combines Biointron’s rapid 1-day transient CHO expression technology with antibody characterization and early developability testing to generate standardized, structured datasets optimized for AI and machine learning applications.
The launch comes as AI models rapidly expand the ability to generate hundreds or thousands of antibody candidates in a single design cycle. However, experimental validation has struggled to keep pace, with expression, binding analysis and developability assessments often handled through disconnected workflows that can take three to four weeks or longer.
RushData aims to change that by streamlining the design-build-test-learn cycle and enabling researchers to move from antibody sequence submission to actionable experimental results within days.
Powered by CHO cells — the industry benchmark for therapeutic antibody production — RushData generates biologically relevant data designed to better predict downstream performance. CHO expression supports human-like post-translational modifications, accurate protein folding and clinically relevant developability characteristics.
The platform can process more than 3,000 molecules per batch in parallel, delivering standardized outputs that support both research teams and machine-learning pipelines.
